02348 DAWNRAYS PHARMA
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2024) | |||
| Current | 3.97X | Oper Margin | 60.8% |
|---|---|---|---|
| LT Debt/Equity | 0.1% | Net Margin | 53.3% |
| Total Debt/Equity | 1.0% | Return on Equity | 17.0% |
| Price/Book | 0.57X | Return on Assets | 14.1% |
| (HKD 1.330) | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
| Net Profit (MHKD) | 600.81 | 359.32 | 401.45 | 438.08 | 318.22 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | +67.2 | -10.5 | -8.4 | +37.7 | +11.4 |
| Earnings Per Share (HKD) | 0.399 | 0.24 | 0.268 | 0.293 | 0.206 |
| Earnings Per Share Growth (%) | +66.6 | -10.6 | -8.4 | +42.0 | +13.6 |
| Dividend Per Share (HKD) | 0.095 | 0.080 | 0.088 | 0.080 | 0.115 |
| P/E* (X) | 3.33 | 5.55 | 4.96 | 4.55 | 6.46 |
| Yield (%) | 7.14 | 6.02 | 6.62 | 6.02 | 8.65 |
| Dividend Share (%) | 23.80 | 33.39 | 32.85 | 27.35 | 55.83 |
| Book NAV (HKD) | 2.354 | 2.097 | 1.976 | 1.943 | 1.700 |
| Auditors' Opinion | Unqualified | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2025-07-22 21:40:20
Latest Result
| (RMBMn) | 2024-12 | 2023-12 | Chg* (%) | 2022-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 1,060 | 1,151 | -7.9 | 1,278 |
| Operating Result | 353.975 | 454.99 | -22.2 | 460.643 |
| Associates | -3.696 | -40.933 | -91.0 | -61.905 |
| Profit Before Taxation | 636.949 | 414.057 | +53.8 | 438.408 |
| Taxation | 74.187 | 91.39 | -18.8 | 82.557 |
| Profit /( Loss) After Taxation | 562.762 | 322.667 | +74.4 | 355.851 |
| Minority Interests | -2.178 | -3.333 | -34.7 | -2.206 |
| Net Profit | 564.94 | 326 | +73.3 | 358.057 |
| Earnings Per Share () | 0.3992 | 0.2396 | +66.6 | 0.2679 |
| Dividend Per Share () | 0.0950 | 0.0800 | +18.8 | 0.0880 |
| Announcement Date | 2025-03-28 | 2024-03-22 | NA | 2023-03-26 |
* Annualised
Last Update Time: 2025-07-22 21:40:25
